Inyecciones

Jump to treatment group
Jump to language selector
Jump to navigation
Jump to Content
Jump to Footer

Características

Actualmente hay 3 tipos de productos diferentes disponibles.

Estos productos o bien se inyectan en el cuerpo cavernoso del pene o se insertan por el tubo del pene (uretra) usando un aplicador especial.

Funcionan en 5-10 minutos tras su administración

Tipo de tratamiento

Estas se inyectan en el pene o se insertan usando un aplicador especial, en general justo antes de la relación sexual para producir una erección.

Debe hablar sobre todos los posibles efectos secundarios con su médico/enfermera.

References

1. Feldman HA, Goldstein I, Hatzichristou DG, y col.Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study.J Urol 1994;151: 54-61.
2. Lobb-Rossini K.Erectile dysfunction and its management. Journal of Community Nursing Online 1999;13 (10):1-8.
3. Eardley Ian, Sethia Krishna. Current Investigations and Management. Second Edition. Moby. Pág 1.
4. Dey J, y Shepherd MD. Evaluation and Treatment of Erectile Dysfunction in Men With Diabetes Mellitus. Mayo Clin Proc 2002; 77: 276-82.
5. Kirby Roger, Carson Culley, Goldstein Irwin.Erectile dysfunction. A Clinical Guide. ISIS Medical Media. Pág 25.
6. Eardley I, Sethia K. Erectile Dysfunction. Current Investigations and Management. Second Edition. Moby. Pág 3.
7. Kupelian V, Araujo A, Chiu GR, et al. Relative contributions of modifiable risk factors to erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. Prev Med. 2010;50(1-2):19-25.
8. Hannan JL, Maio MT, Komolova M, et al. Beneficial impact of exercise and obesity interventions on erectile function and its risk factors. J Sex Med . 2009;6 Suppl 3:254-61.
9. Jackson G. The importance of risk factor reduction in erectile dysfunction. Curr Urol Rep. 2007;8(6):463-6.
10. Miller T. Diagnostic evaluation of erectile dysfunction. Am Fam Physician 2000; 61:95-104.
11. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003;89(3):251-3.
12. Billups KL Erectile dysfunction as a marker for vascular disease.Curr Urol Rep. 2005;6(6):439-44.
13. Jackson G, Rosen RC y col. The Second Princeton Consensus on Sexual Dysfunction and Cardiac Risk: New Guidelines for Sexual Medicine. J Sex Med 2006; 3:28-36.
14. Tamler R. Diabetes, obesity, and erectile dysfunction.Gend Med. 2009;6 Suppl 1:4-16.
15. Metabolic Syndrome. http://www.nhlbi.nih.gov/health/dci/Diseases/ms/ms_Tratamientos.html
16. Porst H. Premature ejaculation. Urologe A Jun 2009;48(6):663-74.
17. Safarinejad MR, Hosseini SY.Erectile dysfunction: clinical guidelines (2).Urol J. 2004;1(4):227-39.
18. Alcaraz A et al. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol. 2009 Apr;55(4):864-73
19. Aytaç, Mckinlay & Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999; 84:50-6.
20. Wespes E. Amar E. Eardley I y col. Guidelines of Male Sexual Dysfunction. Eur Assoc Urol. 2009. http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/Male_Sexual_Dysf.pdf
21. European Sexual Dysfunction Alliance. http://www.essm.org/patient-area/erectile_dysf.asp#q2
22. Safarinejad H. Erectile Dysfunction. Clinical Guidelines (1). Urol J, 2004, 3(1):133-147.
23. Physical Activity and Public health Guidelines. American College of Sports Medicine. http://www.acsm.org/AM/Template.cfm?Section=Home_Page&TEMPLATE=CM/HTMLDisplay.cfm&CONTENIDOID=7764
24. Banks, Ian y col.; Assessment, in a General Population of Men, of Men’s Interaction With the Healthcare System to Obtain Phosphodiesterase Tipo 5 Inhibitors; 2008; Joint Congress of the European and International Societies for Sexual Medicine
25. Alianza Europea para el Acceso a una Medicina Segura; La Autopista de la Falsificación; 2008
26. McNeil Jr., Donald G; A Growing Epidemic of Fake Medication in Asia; International Herald Tribune, 20 de Febrero, 2007
27. Santamaría FC. Psycosocial features of the management of erectile dysfunction. Archivos Españoles de Urología. 2010;63(8):693-702.
28. Asociación Europea de Urología. www.urologyweek.org/erectile-dysfunction/erectile-dysfunction
29. Hedon F. Anxiety and erectile dysfunction: a global approach to ED enhances results and quality of life. International Journal of Impotence Resolution. 2003 Apr;15 Suppl 2:S16-9.
30. Clínica Mayo: Técnicas de relajación: esencial para reducir el estrés www.mayoclinic.com/health/erectile-dysfunction/DS00162)
31. Clínica Cleveland: Enfermedad Eréctil http://my.clevelandclinic.org/disorders/Erectile_Disorder_impotence/hic:Psychological _Causes_of_Erectile_Dysfunction.aspx
32. Steidle CP, Stecher VJ, Pace C, et al.Correlation of improved erectile function and rate of successful intercourse with improved emotional well-being assessed with the Self-Esteem And Relationship questionnaire in men treated with sildenafil for erectile dysfunction and stratified by age. Curr Med Res Opin. 2006 May;22(5):939-48.
33. http://www.mayoclinic.com/health/relaxation-technique/SR00007

Wybierz język

Navigation menu

Características

Tipo de tratamiento

Submenu

References

Lilly